GlaxoSmithKline : 3rd Quarter Results

Pharmaceuticals turnover in the nine months was £12,996 million, up 4% AER, 1% CER. Respiratory sales were up 23% AER, 18% CER, to £2,189 million, on growth of TrelegyElliptaand Nucala. HIV sales were up 4% AER, 1% CER, to £3,597 million, with growth in Julucaand Dovatopartly offset by a decline in Triumeq. Sales of Established Pharmaceuticals were £6,603 million, down 4% AER, 6% CER, including the impact of loss of exclusivity of Advair.

In the US, sales grew 2% AER but declined 4% CER. Excluding Advairand Relvar/Breo Ellipta, impacted by genericisation of the ICS/LABA market, growth was 15% AER, 9% CER. Continued growth of Nucala, Trelegy Elliptaand Benlystawas offset by the decline in Established Products including the loss of exclusivity of Advair. In Europe, sales grew 4% AER, 4% CER, with strong growth in Respiratory partly offset by a decline in Established Pharmaceuticals. International grew 7% AER, 6% CER, with growth in all therapy areas.

Respiratory

Total Respiratory sales were up 23% AER, 18% CER, with strong growth in all regions. Elliptaproduct sales grew 17% AER, 13% CER, with Europe up 30% AER, 30% CER and International up 33% AER, 30% CER on Trelegyand Relvar/Breogrowth. Nucalawas up 39% AER, 39% CER in Europe and 65% AER, 56% CER in International. In the US, TrelegyElliptaand Nucalagrowth more than offset the decline in Relvar/BreoElliptaon post generic ICS/LABA price pressure.

Sales of Nucalawere £550 million in the nine months and grew 41% AER, 35% CER, continuing to benefit from the global rollout of the product. US sales of Nucalagrew 37% AER, 29% CER to £321 million.

Sales of Elliptaproducts were up 17% AER, 13% CER to £1,639 million, driven by growth in Europe and International regions. In the US, sales grew 8% AER, 2% CER, reflecting continued competitive pricing pressures for ICS/LABAs, post generic Advair. Sales of Trelegy Elliptacontributed £346 million globally in the nine months, driven by an increase in US market share.

Relvar/Breo Elliptasales were down 7% AER, 10% CER. This was driven by the US, where Relvar/BreoElliptadeclined 31% AER, 35% CER as a result of competitive pricing pressures and the impact of generic Advair on the ICS/LABA market. In Europe and International, Relvar/BreoElliptacontinued to grow, up 14% AER, 14% CER in Europe, and 23% AER, 21% CER in International.

HIV

HIV sales grew 4% AER, 1% CER to £3,597 million in the nine months. The dolutegravir franchise grew 7% AER, 3% CER, delivering sales of £3,425 million. The remaining portfolio, with sales of £172 million (5% of total HIV sales), declined 26% AER, 26% CER and reduced the overall HIV growth by two percentage points.

Sales of dolutegravir products were £3,425 million, with Triumeqand Tivicaydelivering sales of £1,911 million and £1,236 million, respectively. The two-drug regimens, Julucaand Dovato, delivered sales of £278 million in the nine months with combined growth more than offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to the new portfolio.

In the US, following the launch of Dovatoin April 2019, combined sales of the two-drug regimens were £234 million. US dolutegravir sales grew 5% AER but declined 1% CER, reflecting a year-on-year share decline as the business transitions to the new two-drug portfolio, partly offset by a net price benefit. In Europe, Dovatoand Julucareported combined sales of £40 million, and total dolutegravir sales grew 1% AER, 1% CER, with growth in market share more than offsetting price erosion and the timing of clawback payments. International performed strongly with total dolutegravir sales growth of 27% AER, 26% CER, driven by Tivicayand Triumeq.

Oncology

Sales of Zejula, were £163 million in the period from the date of acquisition, comprising £97 million in the US and £66 million in Europe.

Immuno-inflammation

Sales of Benlystain the nine months were up 32% AER, 26% CER to £443 million, including sales of the sub-cutaneous formulation of £189 million. In the US, Benlystagrew 29% AER, 22% CER to £387 million.

Established Pharmaceuticals

Sales of Established Pharmaceuticals in the nine months were £6,603 million, down 4% AER, 6% CER.

Established Respiratory products declined 7% AER, 9% CER to £2,935 million, with the decline in Advair/Seretidepartly offset by higher sales of Ventolinand allergy products. In the US, a generic version of Advairwas launched in February, resulting in a 50% AER, 53% CER decline in the nine months. In Europe, Seretidesales were down 15% AER, 15% CER to £383 million, reflecting continued competition from generic products and the transition of the Respiratory portfolio to newer products. In International, sales of Seretidegrew 1% AER but were flat at CER. Globally, Ventolingrew by 36% AER, 32% CER, driven by the strong uptake of an authorised generic version in the US.

The remainder of the Established Pharmaceuticals portfolio declined 2% AER, 3% CER to £3,668 million, with Lamictal down 8% AER, 11% CER to £421 million on generic competition in the US and International, partly offset by growth in Augmentinin the nine months and a European Relenzatender.